RET
Read More about this categoryShow Less
RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.
RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.
Products Related to RET(32)
- GC65354EnbezotinibCAS: 2359649-81-1Purity: >99.00%
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.
- GC81325VEGFR2-IN-84CAS: 861877-12-5Purity: >98%
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC65354 | Enbezotinib | 2359649-81-1 | >99.00% | |
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. | ||||
| GC67917 | RET-IN-7 | 2763386-05-4 | >98% | |
| GC68396 | Vepafestinib | 2129515-96-2 | >98.00% | |
| GC68623 | AD57 | 1093380-42-7 | >98.00% | |
AD57 is a type of orally active multi-kinase inhibitor that inhibits the activity of RET, BRAF, S6K and Src, but has significantly reduced activity against mTOR. | ||||
| GC68812 | BT44 | 924759-42-2 | >99.00% | |
BT44 is a selective RET activator. It can penetrate the blood-brain barrier and can be used for research on neurodegenerative diseases and diabetes. | ||||
| GC73196 | RET-IN-21 | 2414373-42-3 | >97.00% | |
RET-IN-21 is an inhibitor of receptor tyrosine kinase (RET), with the IC50 of 4.4 μM, that has antitumor activity. | ||||
| GC79484 | APS03118 | 2598870-24-5 | >98.50% | |
APS03118 is an orally active, potent and selective rearranged during transfection ( RET ) inhibitor. | ||||
| GC81325 | VEGFR2-IN-84 | 861877-12-5 | >98% | |
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. | ||||
